Investigators inoculated 28 calves with a tripartite respiratory challenge consisting of Mycoplasma bovis, bovine coronavirus, and influenza D virus. Fourteen animals received metaphylactic tilmicosin, while the remainder did not receive this antibiotic regimen. The source abstract did not report specific dosing schedules, sampling timepoints, or detailed experimental procedures in the text provided here; those methodological specifics are in the full manuscript and supplementary material not reproduced in the abstract.
The study team applied unsupervised clustering to longitudinal health scores to partition animals into mild, moderate, and severe clinical trajectories. This approach grouped calves by the course of observable illness rather than by single timepoint measures. The resulting phenotypes permitted comparison of pathogen burden, inflammatory markers, and microbiota features across divergent clinical outcomes.
Data indicated that severe BRDC correlated with higher and more persistent nasal influenza D virus (IDV) loads. Yet pathogen replication measured from nasal samples did not fully account for the wide inter-individual variability in clinical severity. Calves treated with tilmicosin developed substantially milder disease despite having comparable pathogen loads to untreated animals, and the treated group exhibited lower systemic inflammation according to the abstract. Investigators therefore inferred that host–pathogen interactions and host inflammatory responses, rather than pathogen quantity alone, drove important differences in clinical outcome.
Measures of nasal microbial diversity did not consistently predict disease severity across the cohort; simple alpha-diversity metrics were not uniformly explanatory. However, the calves that ultimately developed severe disease displayed a more homogeneous nasal microbiota before inoculation. The authors observed this pre-infection community structure as a potential susceptibility marker, implying that an initially less variable nasal bacterial community may predispose to worse respiratory outcomes when challenged.
The most robust disease-associated microbial signatures were found in the faecal microbiota. Antibiotic-associated dysbiosis in the gut correlated with BRDC severity and with measures of systemic inflammation. Faecal short-chain fatty acid (SCFA) profiles were linked to disease outcomes as well; specific SCFA concentrations tracked with both inflammatory biomarkers and clinical phenotype. The abstract indicates these gut-derived metabolic signals and taxonomic shifts were stronger correlates of severity than upper-respiratory microbial diversity in this experimental setting.
Among taxa reported in the abstract, Chlamydia abundance showed a strong association with disease severity. The study team also reported multiple other intestinal taxa correlated with inflammatory biomarkers and faecal SCFA concentrations, though the abstract did not list those taxa exhaustively. Readers seeking the full taxa-level statistical associations should consult the main manuscript and supplementary tables referenced in the source.
Authors framed their results within a holobiont-driven model of Bovine respiratory disease complex (BRDC) where clinical severity emerges from interactions among pathogens, the host inflammatory response, and microbiota-associated functions. The stronger signals coming from the intestine, together with links between gut bacteria, SCFAs, and disease outcomes, provide empirical support for a functional gut-lung axis in calves according to the abstract. Microbial metabolism therefore appears as a candidate intervention target to modulate respiratory health and potentially reduce antibiotic reliance.
This report is a preprint and has not been peer reviewed, a limitation the authors declared. The abstract does not present detailed dosing regimens for tilmicosin, full time-resolved sampling schemas, or the complete list of taxa and statistical outputs; those details are available in the full preprint and supplementary files. Key unanswered questions documented in the source include the mechanisms by which specific gut taxa or SCFAs mechanistically influence lung inflammation, whether the identified microbial associations generalize to natural BRDC outbreaks outside this controlled challenge model, and which microbiome-directed interventions would safely alter disease trajectories. These items remain to be addressed in subsequent peer-reviewed work and experimental follow-ups.